The Effect of Dabigatran Plasma Concentrations and Patient Characteristics on the Frequency of Ischemic Stroke and Major Bleeding in Atrial Fibrillation Patients

This publication has 17 references indexed in Scilit:

• A combined pharmacometric analysis of dabigatran etexilate in healthy volunteers and patients with atrial fibrillation or undergoing orthopaedic surgery
  Thrombosis and Haemostasis, 2012
• Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non‐valvular atrial fibrillation from the RE‐LY trial
  Journal of Thrombosis and Haemostasis, 2011
• Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation
  Circulation, 2011
• Comparative Validation of a Novel Risk Score for Predicting Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation
  Journal of the American College of Cardiology, 2011
• Newly Identified Events in the RE-LY Trial
  New England Journal of Medicine, 2010
• The Metabolism and Disposition of the Oral Direct Thrombin Inhibitor, Dabigatran, in Humans
  Drug Metabolism and Disposition, 2008
• Clinical Pharmacokinetics and Pharmacodynamics of the Oral Direct Thrombin??Inhibitor Dabigatran Etexilate
  Clinical Pharmacokinetics, 2008
• BAY 59-7939: an oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study
  Journal of Thrombosis and Haemostasis, 2005
• A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial
  Journal of Thrombosis and Haemostasis, 2005
• A Synthetic Pentasaccharide for the Prevention of Deep-Vein Thrombosis after Total Hip Replacement
  New England Journal of Medicine, 2001